Background: In recent years, proton pump inhibitors (PPIs) have been investigated at high-dose\nto modulate tumor microenvironment acidification thus restoring chemotherapeutic sensitivity. This is the\nfirst trial to study activity and safety of repurposing high dose rabeprazole combined with metronomic\ncapecitabine (mCAP). Methods: A phase II study in which patients with gastrointestinal cancer,\nrefractory to standard treatments, who had a life expectancy...............................
Loading....